UPLOAD Filing
Genprex, Inc.
Date: Sept. 11, 2025 · CIK: 0001595248 · Accession: 0000000000-25-009862
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Genprex, Inc. Draft Registration Statement on Form S-1 Submitted September 5, 2025 CIK No. 0001595248 Dear Ryan Confer:
September 11, 2025
Ryan Confer Chief Executive Officer Genprex, Inc. 3300 Bee Cave Road #650-227 Austin, TX 78746
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Kate Basmagian, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 11, 2025 Ryan Confer Chief Executive Officer Genprex, Inc. 3300 Bee Cave Road #650-227 Austin, TX 78746 Re: Genprex, Inc. Draft Registration Statement on Form S-1 Submitted September 5, 2025 CIK No. 0001595248 Dear Ryan Confer: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kate Basmagian, Esq. </TEXT> </DOCUMENT>